Cormorant Global Healthcare Master Fund, LP — SEC insider filings
SEC reporting owner CIK 1618442. 56 insider filings on record with FilingPulse; latest filed 2026-11-02.
Transaction summary — filings shown
Covers the 50 most recent of 56 filings on record, filed 2021-04-22 to 2026-11-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 97 legs across 32 filings — 26,964,849 shares, $407,220,218 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 25 legs across 10 filings — 19,459,827 shares, $67,002,758 total (shares × price as filed on priced legs).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 40.
- Largest priced transaction: purchase of 3,376,646 shares @ $11.27 ($38,053,112) in Ambrx Biopharma Inc., filed 2023-04-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ambrx Biopharma Inc. (AMAM) | 10% owner | 4 | 11 legs · 10,965,823 sh · $114,106,979 | — | — |
| EyePoint, Inc. (EYPT) | — | 6 | 24 legs · 4,794,057 sh · $89,496,413 | 1 leg · 60,000 sh · $942,240 | — |
| MoonLake Immunotherapeutics (MLTX) | — | 3 | 4 legs · 352,051 sh · $20,324,640 | 5 legs · 6,499,978 sh · $46,868,184 | — |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | — | 6 | 31 legs · 1,932,632 sh · $53,693,261 | 2 legs · 455,029 sh · $2,086,767 | — |
| Biomea Fusion, Inc. (BMEA) | — | 7 | 2 legs · 1,300,000 sh · $27,300,000 | — | 6 |
| Erasca, Inc. (ERAS) | Director | 4 | 3 legs · 1,565,384 sh · $19,199,996 | — | 5 |
| BRIGHT MINDS BIOSCIENCES INC. (DRUG) | — | 2 | 11 legs · 422,591 sh · $3,234,387 | 1 leg · 109,331 sh · $9,785,124 | — |
| Immuneering Corp (IMRX) | 10% owner | 3 | 1 leg · 550,000 sh · $8,250,000 | 13 legs · 1,309,091 sh · $3,909,184 | 2 |
| Monte Rosa Therapeutics, Inc. (GLUE) | 10% owner | 1 | 1 leg · 600,000 sh · $11,400,000 | — | 3 |
| Ventyx Biosciences, Inc. (VTYX) | — | 1 | 1 leg · 625,000 sh · $10,000,000 | — | 3 |
+12 more issuers among the filings shown — every filing appears in the table below.
Insider filings — Cormorant Global Healthcare Master Fund, LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-02 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Chen Bihua | Sale (S): 425,000 @ $4.10 | EDGAR |
| 2026-08-10 | 4 | BlossomHill Therapeutics, Inc. (BLSM) jointly with Chen Bihua, Cormorant Asset Management, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund V LP, Cormorant Private Healthcare Fund VI, LP | Conversion (C): 1,599,993 · Conversion (C): 1,701,541 · Purchase (P): 312,500 @ $16 · Grant/award (A): 23,904 (derivative) @ $0 · Conversion (C): 1,599,993 (derivative) · Conversion (C): 1,701,541 (derivative) | EDGAR |
| 2026-04-30 | 4 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) jointly with Cormorant Asset Management, LP, Chen Bihua | Sale (S): 109,331 @ $89.50 | EDGAR |
| 2025-12-15 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Chen Bihua | Sale (S): 30,029 @ $11.46 | EDGAR |
| 2025-12-08 | 4 | EyePoint, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Chen Bihua | Sale (S): 60,000 @ $15.70 | EDGAR |
| 2025-10-01 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Chen Bihua, Cormorant Asset Management, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Sale (S): 70,748 @ $9.38 · Sale (S): 232,460 @ $8.40 · Sale (S): 3,390,943 @ $7.58 · Sale (S): 2,800,000 @ $6.61 · Sale (S): 5,827 @ $6.96 | EDGAR |
| 2025-08-01 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Holdings only — no transactions reported | EDGAR |
| 2025-06-13 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Grant/award (A): 91,970 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | OnKure Therapeutics, Inc. (OKUR) jointly with Cormorant Asset Management, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP, Cormorant Private Healthcare Fund V LP, Chen Bihua | Sale (S): 1,813,439 @ $1.85 | EDGAR |
| 2025-05-14 | 4 | OnKure Therapeutics, Inc. (OKUR) jointly with Cormorant Asset Management, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP, Cormorant Private Healthcare Fund V LP, Chen Bihua | Sale (S): 24,300 @ $1.99 | EDGAR |
| 2024-10-17 | 4 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 238,097 @ $4.53 · Purchase (P): 63,173 @ $5.92 · Purchase (P): 33,343 @ $6.42 · Purchase (P): 8,900 @ $7.31 · Purchase (P): 2,600 @ $8.80 · Purchase (P): 2,700 @ $9.26 · +5 more | EDGAR |
| 2024-09-24 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 45,085 @ $17.48 · Purchase (P): 25,943 @ $18.36 · Purchase (P): 66,088 @ $19.61 · Purchase (P): 139,551 @ $20.42 · Purchase (P): 47,564 @ $21.47 · Purchase (P): 25,769 @ $22.23 | EDGAR |
| 2024-06-13 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Grant/award (A): 51,025 (derivative) @ $0 | EDGAR |
| 2024-05-08 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 642,847 @ $11.70 · Purchase (P): 207,153 @ $12.36 | EDGAR |
| 2024-04-22 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 395,244 @ $17.62 · Purchase (P): 186,521 @ $18.90 | EDGAR |
| 2024-04-03 | 4 | Immuneering Corp (IMRX) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Sale (S): 100 @ $3.07 · Sale (S): 300 @ $3.06 · Sale (S): 100 @ $3.05 · Sale (S): 600 @ $3.03 · Sale (S): 10 @ $3.01 · Sale (S): 10 @ $2.98 · +2 more | EDGAR |
| 2024-03-18 | 4 | Immuneering Corp (IMRX) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Sale (S): 345,266 @ $3.23 · Sale (S): 98,570 @ $4.25 · Sale (S): 54,215 @ $5.37 · Sale (S): 11,040 @ $5.97 · Sale (S): 400,000 @ $2.14 | EDGAR |
| 2024-03-11 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 46,799 @ $37.82 · Purchase (P): 10,736 @ $39.13 · Purchase (P): 90,325 @ $39.99 · Purchase (P): 102,140 @ $41.23 · Purchase (P): 29,342 @ $41.23 · Purchase (P): 24,983 @ $42.25 · +4 more | EDGAR |
| 2024-02-06 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 750,000 @ $19 | EDGAR |
| 2024-01-30 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 14,388 @ $25.73 · Purchase (P): 15,243 @ $26.66 · Purchase (P): 36,747 @ $27.70 · Purchase (P): 31,028 @ $28.82 · Purchase (P): 29,244 @ $29.42 · Purchase (P): 2,654 @ $31 · +8 more | EDGAR |
| 2024-01-11 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 105,000 @ $21.32 · Purchase (P): 750,000 @ $19.75 | EDGAR |
| 2023-12-12 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 588,235 @ $17 | EDGAR |
| 2023-12-06 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Chen Bihua | Purchase (P): 321,259 @ $18.80 · Purchase (P): 945,664 @ $19.88 · Purchase (P): 122,625 @ $20.62 · Purchase (P): 79,805 @ $21.87 · Purchase (P): 28,090 @ $22.80 · Purchase (P): 37,081 @ $24.01 · +11 more | EDGAR |
| 2023-10-25 | 4 | Ambrx Biopharma, Inc. (AMAM) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,307,311 @ $6.99 | EDGAR |
| 2023-10-10 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Chen Bihua, Cormorant Asset Management, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Purchase (P): 58,839 @ $59.90 | EDGAR |
| 2023-10-04 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Chen Bihua, Cormorant Asset Management, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Purchase (P): 74,911 @ $57.37 · Purchase (P): 150,487 @ $57.25 · Purchase (P): 67,814 @ $57.32 | EDGAR |
| 2023-09-19 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,401,505 @ $9.05 · Purchase (P): 751,233 @ $9.24 | EDGAR |
| 2023-07-24 | 4 | GreenLight Biosciences Holdings, PBC (GRNA) jointly with Cormorant Asset Management, LP, Cormorant Private Healthcare Fund II, LP, Chen Bihua | Sale (S): 9,188,659 @ $0 | EDGAR |
| 2023-06-26 | 4 | Erasca, Inc. (ERAS) jointly with Chen Bihua, Cormorant Asset Management, LP, Cormorant Private Healthcare Fund II, LP | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Grant/award (A): 6,989 (derivative) @ $0 | EDGAR |
| 2023-04-20 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Purchase (P): 3,376,646 @ $11.27 · Purchase (P): 951,909 @ $11.15 · Purchase (P): 886,634 @ $11.60 | EDGAR |
| 2023-04-17 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,193,808 @ $9.16 · Purchase (P): 841,967 @ $9.96 · Purchase (P): 562,121 @ $10.67 | EDGAR |
| 2023-04-03 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Purchase (P): 400,000 @ $30 | EDGAR |
| 2023-03-16 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Purchase (P): 250,000 @ $9.95 · Purchase (P): 250,000 @ $10.60 · Purchase (P): 500,000 @ $10.15 | EDGAR |
| 2022-12-21 | 4/A | Erasca, Inc. (ERAS) jointly with Chen Bihua, Cormorant Asset Management, LP, Cormorant Private Healthcare Fund II, LP | Purchase (P): 307,692 @ $6.50 | EDGAR |
| 2022-12-20 | 4 | Erasca, Inc. (ERAS) jointly with Chen Bihua, Cormorant Asset Management, LP, Cormorant Private Healthcare Fund II, LP | Purchase (P): 307,692 @ $6.50 | EDGAR |
| 2022-06-24 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Grant/award (A): 23,867 (derivative) @ $0 | EDGAR |
| 2022-01-13 | 4 | Vigil Neuroscience, Inc. (VIGL) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund IV LP | Conversion (C): 616,786 · Conversion (C): 616,786 (derivative) | EDGAR |
| 2021-10-27 | 4 | Ventyx Biosciences, Inc. (VTYX) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Conversion (C): 785,303 · Purchase (P): 625,000 @ $16 · Conversion (C): 548,288 (derivative) · Conversion (C): 237,015 (derivative) | EDGAR |
| 2021-10-15 | 4 | Pyxis Oncology, Inc. (PYXS) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Conversion (C): 668,854 · Purchase (P): 450,000 @ $16 · Conversion (C): 668,854 (derivative) | EDGAR |
| 2021-09-21 | 4 | Tyra Biosciences, Inc. (TYRA) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Conversion (C): 757,432 · Purchase (P): 312,500 @ $16 · Conversion (C): 757,432 (derivative) | EDGAR |
| 2021-08-05 | 4 | Immuneering Corp (IMRX) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Conversion (C): 1,702,628 · Purchase (P): 550,000 @ $15 · Conversion (C): 1,702,628 (derivative) | EDGAR |
| 2021-08-04 | 4 | Icosavax, Inc. (ICVX) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Conversion (C): 426,393 · Conversion (C): 426,393 (derivative) | EDGAR |
| 2021-07-22 | 4 | Erasca, Inc. (ERAS) jointly with Chen Bihua, Cormorant Asset Management, LP, Cormorant Private Healthcare Fund II, LP | Conversion (C): 9,555,553 · Purchase (P): 950,000 @ $16 · Conversion (C): 4,000,000 (derivative) · Conversion (C): 4,166,666 (derivative) · Conversion (C): 1,388,887 (derivative) | EDGAR |
| 2021-07-07 | 4 | Aerovate Therapeutics, Inc. (AVTE) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund II, LP | Conversion (C): 1,530,691 · Purchase (P): 500,000 @ $14 · Conversion (C): 1,530,691 (derivative) | EDGAR |
| 2021-07-01 | 4 | Elevation Oncology, Inc. (ELEV) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Conversion (C): 1,983,168 · Purchase (P): 250,000 @ $16 · Conversion (C): 1,983,168 (derivative) | EDGAR |
| 2021-06-30 | 4 | Monte Rosa Therapeutics, Inc. (GLUE) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund II, LP | Conversion (C): 2,602,200 · Purchase (P): 600,000 @ $19 · Conversion (C): 2,124,343 (derivative) · Conversion (C): 477,857 (derivative) | EDGAR |
| 2021-06-23 | 4 | Verve Therapeutics, Inc. (VERV) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP | Conversion (C): 709,224 · Purchase (P): 275,000 @ $19 · Conversion (C): 709,224 (derivative) | EDGAR |
| 2021-04-29 | 4 | Rain Therapeutics Inc. (RAIN) jointly with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund II, LP | Conversion (C): 2,326,657 · Purchase (P): 450,000 @ $17 · Conversion (C): 2,512,561 (derivative) | EDGAR |
| 2021-04-22 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Chen Bihua, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Conversion (C): 2,270,872 · Purchase (P): 900,000 @ $17 · Conversion (C): 2,270,872 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1618442 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs